The field of anti-CD19 CAR T-cell development in B-NHL and B-ALL is rapidly expanding, with several additional studies being recently reported (34–39), and more than 100 clinical trials currently registered worldwide. Here, CD19 is linked to non-Hodgkin lymphoma.